149 related articles for article (PubMed ID: 22615592)
1. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT(1A) recaptors.
Mohajjel Nayebi A A; Sheidaei H
Daru; 2010; 18(1):41-5. PubMed ID: 22615592
[TBL] [Abstract][Full Text] [Related]
2. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats.
Nayebi AM; Rad SR; Saberian M; Azimzadeh S; Samini M
Pharmacol Rep; 2010; 62(2):258-64. PubMed ID: 20508280
[TBL] [Abstract][Full Text] [Related]
3. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy.
Haleem DJ; Shireen E; Haleem MA
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1323-9. PubMed ID: 15588759
[TBL] [Abstract][Full Text] [Related]
4. The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms.
Ahmadi SA; Sabahi M; Haddadi R
Neuropsychopharmacol Hung; 2019 Jun; 21(2):59-68. PubMed ID: 31378723
[TBL] [Abstract][Full Text] [Related]
5. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of chlorpromazine-induced catalepsy by the 5-HT-1A ligands pindolol and buspirone in mice.
Silva SR; Futuro-Neto HA; Pires JG
Braz J Med Biol Res; 1990; 23(9):869-71. PubMed ID: 2101330
[TBL] [Abstract][Full Text] [Related]
7. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice.
Egashira N; Matsuda T; Koushi E; Mishima K; Iwasaki K; Shoyama Y; Fujiwara M
Eur J Pharmacol; 2006 Nov; 550(1-3):117-22. PubMed ID: 17022969
[TBL] [Abstract][Full Text] [Related]
8. Role of 5-Hydroxytryptamine 1A Receptors in 6-Hydroxydopmaine-induced Catalepsy-like Immobilization in Rats: a Therapeutic Approach for Treating Catalepsy of Parkinson's Disease.
Eyhani-Rad S; Mohajjel Nayebi A; Mahmoudi J; Samini M; Babapour V
Iran J Pharm Res; 2012; 11(4):1175-81. PubMed ID: 24250551
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
10. The effect of serotonergic agents on haloperidol-induced catalepsy.
Hicks PB
Life Sci; 1990; 47(18):1609-15. PubMed ID: 2250574
[TBL] [Abstract][Full Text] [Related]
11. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.
Sharifi H; Mohajjel Nayebia A; Farajnia S
Adv Pharm Bull; 2012; 2(1):127-31. PubMed ID: 24312782
[TBL] [Abstract][Full Text] [Related]
12. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.
Prinssen EP; Colpaert FC; Koek W
Eur J Pharmacol; 2002 Oct; 453(2-3):217-21. PubMed ID: 12398907
[TBL] [Abstract][Full Text] [Related]
13. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635.
Collinson N; Dawson GR
Psychopharmacology (Berl); 1997 Jul; 132(1):35-43. PubMed ID: 9272757
[TBL] [Abstract][Full Text] [Related]
14. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
[TBL] [Abstract][Full Text] [Related]
15. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
Neuropharmacology; 2008 Oct; 55(5):717-23. PubMed ID: 18585397
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Garcia J; Winkler C; Björklund A; Carta M
Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
[TBL] [Abstract][Full Text] [Related]
17. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders.
Shimizu S; Tatara A; Imaki J; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):877-81. PubMed ID: 20398719
[TBL] [Abstract][Full Text] [Related]
18. Involvement of presynaptic 5-HT
Mombereau C; Arnt J; Mørk A
Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
[TBL] [Abstract][Full Text] [Related]
19. Effects of the 5-HT receptor antagonists cyanopindolol, ICI 169,369, cisapride and granisetron on neuroleptic-induced catalepsy in mice.
Pires JG; Ramage AG; Silva SR; Futuro-Neto HA
Braz J Med Biol Res; 1993 Aug; 26(8):847-52. PubMed ID: 8298521
[TBL] [Abstract][Full Text] [Related]
20. Modification of the discriminative stimulus effects of 8-OH-DPAT, buspirone and the beta-adrenoreceptor antagonist pindolol after chronic administration of the 5-HT(1A) agonist 8-OH-DPAT in the pigeon.
Zhang L; Barrett JE
Behav Pharmacol; 1991 Nov; 2(4 And 5):369-378. PubMed ID: 11224080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
